Atara Biotherapeutics Inc (NASDAQ:ATRA) CEO Isaac E. Ciechanover sold 20,000 shares of Atara Biotherapeutics stock in a transaction dated Wednesday, February 14th. The stock was sold at an average price of $46.80, for a total value of $936,000.00. Following the sale, the chief executive officer now directly owns 808,675 shares of the company’s stock, valued at $37,845,990. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink.
Atara Biotherapeutics Inc (ATRA) traded up $3.30 during trading on Wednesday, hitting $48.35. The stock had a trading volume of 1,427,869 shares, compared to its average volume of 1,256,386. Atara Biotherapeutics Inc has a fifty-two week low of $11.80 and a fifty-two week high of $49.90. The stock has a market cap of $1,480.00, a P/E ratio of -13.93 and a beta of 2.71.
A number of analysts have issued reports on the company. Citigroup raised Atara Biotherapeutics from a “sell” rating to a “neutral” rating and set a $18.00 price target for the company in a report on Wednesday, January 3rd. Canaccord Genuity reissued a “positive” rating and issued a $70.00 target price (up from $47.00) on shares of Atara Biotherapeutics in a report on Friday, January 19th. BidaskClub raised Atara Biotherapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday. Cowen started coverage on Atara Biotherapeutics in a report on Friday, January 26th. They issued an “outperform” rating for the company. Finally, Zacks Investment Research downgraded Atara Biotherapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, February 6th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The stock currently has an average rating of “Buy” and a consensus target price of $30.60.
Atara Biotherapeutics Company Profile
Atara Biotherapeutics, Inc is a clinical-stage biopharmaceutical company. The Company is focused on developing therapies for patients with severe and life-threatening diseases. The Company operates through the business of developing and commercializing therapeutics segment. The Company is focused on developing allogeneic or third-party derived antigen-specific T-cells.
Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.